Cellceutix Stockholders Tour Company Facilities at First Annual Stockholder Meeting; Investors Express Support for Company and Disgust for Seeking Alpha Article - Seite 2

D. Proposal 4: Advisory Vote on Frequency of Future Votes on Executive Compensation

III. VOTING

A. Voting Procedures
B. Opening Polls
C. Voting on Proposals
D. Closing Polls

IV. REPORT OF MEETING RESULTS
The Secretary of the meeting, Mr. David Crandall of Hogan Lovells US LLP, announced the results of the voting.

"Each of the five nominees for election to the Board of Directors has received the requisite number of votes required for election. The proposal regarding the ratification of Baker Tilly Virchow Krause, LLP as the independent registered public accounting firm has been approved. The proposal regarding executive compensation has received the requisite number of votes for approval. The proposal regarding the frequency in which to hold future stockholder votes on executive compensation has been voted at one year. I will prepare a written certificate documenting the results of the voting and certain other matters."

V. ADJOURNMENT

VI. QUESTIONS AND ANSWERS -Board and Auditors

*A suggestion was made to the Board of Directors and the Compensation Committee that executive bonuses, such as stock options and warrants, be contingent upon stock performance (the shareholder mentioned $3 per share for CTIX stock) and other corporate developments, such as uplisting to a senior exchange.

VII. MANAGEMENT- COMPANY PRESENTATION

1. Dr. Jorgensen's presentation discussed the Company's press release of December 14, 2015, which included:

Start of Kevetrin advanced study in ovarian cancer;
Start of Brilacidin ABSSSI Phase 3;
Start of Brilacidin for Ulcerative Proctitis proof of concept trial (phase 2);
Top line data on Kevetrin Phase 1 trial for advanced solid tumors;
Top line data on Prurisol Phase 2 trial for chronic plaque psoriasis;
Interim analysis for Brilacidin Phase 2 trial for Oral Mucositis;
Start of Retinoblastoma program, formulation and toxicity studies;
Additional ototoxicity studies with Brilacidin in different concentrations;
Gram- negative and anti-fungal progress;
Submission of grant application for study of Kevetrin in Pancreatic cancer with renowned hospital.
(See: http://cellceutix.com/cellceutix-first-annual-shareholder-meeting-december-15-2015/#sthash.apJz7TDR.dpbs)

2. Mr. Ehrlich read an email received the preceding day from a shareholder and his response.